Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.
You may also be interested in...
With Generous Partner Abbott Back For More, Reata Aims High Again
Texas biotech Reata can add another $400 million license deal, its second with Abbott, to the $178 million it has raised from venture backers. But this time it's for preclinical assets.
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
The Phase IIb study shows the drug can reverse the progression of chronic kidney disease, making it a potential first-in-class treatment.
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
The Phase IIb study shows the drug can reverse the progression of chronic kidney disease, making it a potential first-in-class treatment.